Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I-II Trial of Combined PKCι and mTOR Inhibition for Patients With Advanced or Recurrent Lung Cancer (NSCLC and SCLC) Without Standard Treatment Options

Trial Profile

A Phase I-II Trial of Combined PKCι and mTOR Inhibition for Patients With Advanced or Recurrent Lung Cancer (NSCLC and SCLC) Without Standard Treatment Options

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 26 Feb 2019

At a glance

  • Drugs Auranofin (Primary) ; Sirolimus (Primary)
  • Indications Adenocarcinoma; Lung cancer; Non-small cell lung cancer; Small cell lung cancer; Squamous cell cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 21 Feb 2019 Planned End Date changed from 1 Nov 2019 to 21 Aug 2020.
    • 21 Feb 2019 Planned primary completion date changed from 1 Nov 2019 to 21 Aug 2020.
    • 03 Jan 2019 Planned End Date changed from 1 Nov 2018 to 1 Nov 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top